AU2007245495A1 - Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds - Google Patents

Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds Download PDF

Info

Publication number
AU2007245495A1
AU2007245495A1 AU2007245495A AU2007245495A AU2007245495A1 AU 2007245495 A1 AU2007245495 A1 AU 2007245495A1 AU 2007245495 A AU2007245495 A AU 2007245495A AU 2007245495 A AU2007245495 A AU 2007245495A AU 2007245495 A1 AU2007245495 A1 AU 2007245495A1
Authority
AU
Australia
Prior art keywords
independently
alkyl
compound according
nrn
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007245495A
Other languages
English (en)
Inventor
Lawrence Davies
Harmen Dijkstra
Richard Malcolm Marais
Delphine Menard
Dan Niculescu-Duvaz
Ion Niculescu-Duvaz
Arnaud Nourry
Caroline Joy Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0608268.9A external-priority patent/GB0608268D0/en
Application filed by Institute of Cancer Research Royal Cancer Hospital, Cancer Research Technology Ltd, Astex Therapeutics Ltd filed Critical Institute of Cancer Research Royal Cancer Hospital
Publication of AU2007245495A1 publication Critical patent/AU2007245495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007245495A 2006-04-26 2007-04-26 Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds Abandoned AU2007245495A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74563306P 2006-04-26 2006-04-26
US60/745,633 2006-04-26
GB0608268.9 2006-04-26
GBGB0608268.9A GB0608268D0 (en) 2006-04-26 2006-04-26 Therapeutic compounds
PCT/GB2007/001534 WO2007125330A1 (en) 2006-04-26 2007-04-26 Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds

Publications (1)

Publication Number Publication Date
AU2007245495A1 true AU2007245495A1 (en) 2007-11-08

Family

ID=38421488

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007245495A Abandoned AU2007245495A1 (en) 2006-04-26 2007-04-26 Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds

Country Status (7)

Country Link
US (1) US7951819B2 (enExample)
EP (1) EP2013207B1 (enExample)
JP (1) JP2009534457A (enExample)
AU (1) AU2007245495A1 (enExample)
CA (1) CA2649994A1 (enExample)
NO (1) NO20084688L (enExample)
WO (1) WO2007125330A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073513A1 (en) * 2007-11-30 2009-06-11 Schering Corporation Braf biomarkers
CN101945869B (zh) 2007-12-19 2014-06-18 癌症研究技术有限公司 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
GB0807609D0 (en) * 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
WO2011092469A1 (en) 2010-02-01 2011-08-04 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP2560722A2 (en) 2010-04-21 2013-02-27 The Regents of the University of Michigan Fluoroscopy-independent, endovascular aortic occlusion system
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
EP2739143B1 (en) * 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
US9474882B2 (en) 2013-02-26 2016-10-25 Prytime Medical Devices, Inc. Fluoroscopy-independent balloon guided occlusion catheter and methods
CA2923419A1 (en) 2013-09-09 2015-03-12 Pryor Medical Devices, Inc. Low-profile occlusion catheter
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
WO2015191685A1 (en) 2014-06-10 2015-12-17 Pryor Medical Devices, Inc. Conduit guiding tip
WO2016149653A2 (en) 2015-03-19 2016-09-22 Prytime Medical Devices, Inc. System and method for low-profile occlusion balloon catheter
CA2990479C (en) 2016-06-02 2019-03-26 Prytime Medical Devices, Inc. System and method for low-profile occlusion balloon catheter
CA3034239A1 (en) * 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
WO2018132623A1 (en) 2017-01-12 2018-07-19 The Regents Of The University Of California Endovascular perfusion augmentation for critical care
HUE069643T2 (hu) 2017-03-27 2025-03-28 Hydro Quebec Elektrolitkeverékekben vagy elektródaadalékként való felhasználásra szánt sók
CN110769749B (zh) 2017-04-21 2023-05-09 加利福尼亚大学董事会 用于部分主动脉闭塞的主动脉流量计和泵
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
EP3833273A4 (en) 2018-08-06 2022-06-29 Prytime Medical Devices, Inc. System and method for low profile occlusion balloon catheter
PE20221034A1 (es) 2019-08-08 2022-06-17 B C I Pharma Derivados de quinolina como inhibidores de proteina quinasa
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
CN112574176B (zh) * 2019-09-27 2024-03-15 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
AU2021239935A1 (en) 2020-03-16 2022-10-06 Certus Critical Care, Inc. Blood flow control devices, systems, and methods and error detection thereof
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
EP4084703B1 (en) 2021-03-18 2024-03-13 Prytime Medical Devices, Inc. Vascular occlusion catheter
TWI812301B (zh) * 2021-06-24 2023-08-11 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
EP4622971A1 (en) 2022-11-24 2025-10-01 B.C.I. Pharma Pyridine derivatives as protein kinase inhibitors
WO2025021943A1 (en) 2023-07-26 2025-01-30 Neuralis Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5665863A (en) 1979-10-31 1981-06-03 Tokyo Organ Chem Ind Ltd Novel aniline derivative, its preparation and pesticide containing the same
JPS5738777A (en) 1980-08-19 1982-03-03 Sogo Yatsukou Kk 2-sufanilamidopyrathyn derivative
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
JPH10506011A (ja) 1994-09-22 1998-06-16 ヘルシンキ、ユニバーシティ、ライセンシング、リミテッド、オサケ、ユキチュア レセプターチロシンキナーゼ、ｔｉｅのプロモーター
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
UA72448C2 (en) 1997-09-26 2005-03-15 Zentaris Gmbh Azabenzimidazole-based compounds, methods for their synthesis and pharmaceutical composition, method for modulating function of serine/threonine protein kinases with azabenzimidazole-based compounds, method for identifying compounds modulating functioning of serine/threonine protein kinase, method for preventing and treating serine/threonine protein kinase-related abnormal conditions with azabenzimidazole-based compounds
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
GB2356398A (en) 1999-11-18 2001-05-23 Lilly Dev Ct S A Preparation of arylsulfamides
CA2395520A1 (en) 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
NZ532780A (en) 2001-12-21 2006-10-27 Wellcome Trust Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them
JP4335136B2 (ja) 2002-08-09 2009-09-30 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
BRPI0514691A (pt) 2004-08-31 2008-06-17 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds

Also Published As

Publication number Publication date
EP2013207A1 (en) 2009-01-14
US7951819B2 (en) 2011-05-31
WO2007125330A1 (en) 2007-11-08
NO20084688L (no) 2009-01-26
CA2649994A1 (en) 2007-11-08
US20090325945A1 (en) 2009-12-31
EP2013207B1 (en) 2012-04-25
JP2009534457A (ja) 2009-09-24

Similar Documents

Publication Publication Date Title
EP2013207B1 (en) Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
AU2005297089B2 (en) Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds
EP2229391B1 (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
EP1831184B1 (en) Pyrazines and pyridines and derivatives thereof as therapeutic compounds
EP2285805B1 (en) Aryl-quinolyl compounds and their use
NZ572246A (en) Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
HK1100368B (en) Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds
HK1148521B (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application